@entity29 with oral serum-derived XXXX immunoglobulin.

@entity1 @entity31 @entity30 @entity29 @entity291
INTRODUCTION: The clinical effect of oral serum-derived @entity291 immunoglobulin/protein isolate (SBI) on symptom and disease management in @entity1 with @entity29 ( @entity29 ) is reported in this retrospective case series. METHODS: A single-center, retrospective chart review of @entity29 @entity1 [N = 45; @entity30 ( @entity30 ), n = 38 and @entity31 ( @entity31 ), n = 7] with limited to no response to traditional pharmaceutical therapies in controlling symptoms was performed after providing SBI (5 g/day) for nutritional support. @entity1 were contacted at least monthly to assess response to SBI for symptom management measured by a Likert scale (0 = none; 1 = minimal; 2 = moderate; 3 = significant; 4 = complete). Analysis of variance (ANOVA) was performed on response to therapy based on @entity1 characteristics (age, gender, race) and @entity29 diagnosis. A multivariate ordered logistical regression model was performed to determine the odds ratio in overall disease management between week 1 and week 12. Finally, the overall group response and percent improvement to SBI was determined over 12 weeks. RESULTS: The odds ratio from the regression model demonstrated that @entity29 @entity1 were 2.8 times more likely to report clinical improvement in symptom scores with the addition of SBI to their therapeutic regimens [95% confidence interval (CI) 1.266-6.016, p = 0.011]. Disease management was not significantly associated with age, gender, race or disease state. The percentage of @entity1 reporting a response to SBI therapy at week 1 was 49% which increased to 76% after 12 weeks with the fraction of responders gaining significant symptom improvement doubling during the same time period (9% versus 20%). Overall, this group of @entity29 @entity1 showed increased, steady response to SBI therapy between week 1 and 12 with no reported side effects. CONCLUSION: These results suggest that SBI improves clinical management of @entity29 @entity1 who are not fully managed on traditional therapies. SBI should be considered for the nutritional support of @entity29 regardless of disease activity, location, phenotype, duration, or complexity.
